Astute Medical

Astute Medical

Based: San Diego
Raised: $40.45 million
Investors: De Novo Ventures, Delphi Ventures, Domain Associates, Johnson & Johnson Development Corporation, Kaiser Permanente Ventures, MPM Capital

The scoop: This was Astute's third round. The diagnostics company has big plans to start commercialization of its first product. And there are other diagnostic tests in the pipeline that will need further development, reports FierceMedicalDevices. The life sciences company intends to roll out a lineup of tests hospitals will be able to use to assess a slate of symptoms, like abdominal pain and kidney injury. Investors had already put in close to $33 million when the Series C came together. 

Astute Medical
Read more on

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.